Medy-Tox Inc. (KOSDAQ:086900)

Market Cap	1.08T
Revenue (ttm)	228.62B
Net Income (ttm)	15.98B
Shares Out	6.58M
EPS (ttm)	2,376.57
PE Ratio	69.01
Forward PE	28.72
Dividend	1,100.00 (0.69%)
Ex-Dividend Date	Sep 27, 2024

Volume	88,165
Average Volume	72,387
Open	162,300
Previous Close	160,400
Day's Range	158,500 - 164,500
52-Week Range	112,100 - 218,000
Beta	0.42
RSI	52.58
Earnings Date	May 15, 2025

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 721
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2024, Medy-Tox's revenue was 228.62 billion, an increase of 3.39% compared to the previous year's 221.12 billion. Earnings were 15.98 billion, an increase of 82.00%.